fluenza Vaccine (Split Virion), Inactivated, Quadrivalent

Pandemic Influenza Vaccine (Inactivated, Adjuvanted)- Panflu^®

H1N1 Influenza A Vaccine (Split Virion), Inactivated - Panflu.1^®

lSinovac has the most comprehensive portfolio of influenza vaccines

lAnflu^® was launched in 2006 as the first preservative-free trivalent influenza vaccine in China

lThe QIV vaccine, independently developed by Sinovac, was launched in 2020

lThe H5N1 Flu Vaccine, Panflu^®, the first of its kind in China, was approved for national stockpiling in 2008

lThe world’s first H1N1 Flu Vaccine, Panfu.1^®, was approved for launch in 2009 and used for massive inoculation around the world

lThe project “Key Technologies for Evaluation of Pandemic Influenza Vaccines and Immunosorbent: Innovation and Application" won first prize at the Science and Technology Awards from the Chinese Pharmaceutical Association in 2010, first prize at Beijing Scientific and Technological Progress Awards in 2010, and the second prize at the National Scientific and Technological Progress Awards in 2011.

• SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China
  2022/07/04
• SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa
  2022/06/25
• SINOVAC Polio Vaccine Prequalified by WHO
  2022/06/08
• Chilean Report Confirms CoronaVac Safety for Pediatric and Adolescent Population
  2022/05/26
• SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine
  2022/05/11
• SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
  2022/04/30
• China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial
  2022/04/26
• SINOVAC Omicron-specific vaccine approved for clinical trial in Hong Kong
  2022/04/17
• Three doses of SINOVAC COVID-19 vaccine well prevent the worst outcomes during HK Omicron wave
  2022/03/23
• The BRICS Vaccine R&D Center Launched SINOVAC Actively Responds to Common Initiatives
  2022/03/23
• Chile Research: CoronaVac^® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old
  2022/03/16
• Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak
  2022/03/16
• Latest Real-World Data Show Two-shots of CoronaVac^® Provides 74.5% Protection Against COVID-19 For Children and Adolescents
  2022/03/16
• CUHK and SINOVAC Biotech (Hong Kong) Limited strategic collaboration framework agreement signing ceremony
  2022/02/25
• CUHK and SINOVAC join in hands in building P3 laboratory
  2022/02/18
• SINOVAC Reports Unaudited First Half of 2021 Financial Results
  2021/12/31
• SINOVAC CoronaVac® Shows Good Safety in Pregnant and Postpartum Women
  2021/12/29
• South Africa Phase III Clinical Study Shows SINOVAC CoronaVac® Safe for Children as Young as 6 Months
  2021/12/29
• Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
  2021/12/10
• Instituto Butantan and SINOVAC will hold 'CoronaVac® Symposium' international event about efficacy and security of CoronaVac®
  2021/11/29
• The 2nd International Conference on the Latest Researches, Experience Sharing on SINOVAC's COVID-19 Vaccine Was Held
  2021/11/26
• SINOVAC COVID-19 Vaccine Authorized for Commercial Sale in Myanmar
  2021/11/08
• SINOVAC actively discusses COVID-19 Vaccine application and the industry development with other countries
  2021/10/26
• SINOVAC agrees to supply an additional 101,000 doses of COVID-19 vaccines (CoronaVac®) to meet demand for inactivated virus vaccines from Singapore residents
  2021/09/15
• New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
  2021/09/09
• SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
  2021/09/09
• SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
  2021/08/10
• SINOVAC Announces Positive Data on Booster Dose of CoronaVac®
  2021/07/27
• SINOVAC's CoronaVac® Used on Child and Adolescent Population in China, Good Antibody Levels Observed After Three Months Following Vaccination
  2021/07/20
• SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
  2021/07/19
• Clarification Statement
  2021/07/18
• SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
  2021/07/13
• SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
  2021/07/12
• SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
  2021/07/12
• The Lancet Inf. Dis. Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
  2021/07/02
• SINOVAC’s EV71 vaccine Inlive® is approved for children aged from 6 to 71 months
  2021/06/12
• World Health Organization Authorizes SINOVAC’s CoronaVac^® for Emergency Use
  2021/06/02
• EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated
  2021/05/06
• SINOVAC CORPORATE VIDEO (2021)
  2021/04/27
• Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
  2021/04/24
• Summary of Clinical Trial Data of Sinovac’s COVID-19 Vaccine (CoronaVac^®)
  2021/04/03
• Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine
  2021/04/02
• Sinovac Amends Shareholder Rights Plan
  2021/02/22
• Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
  2021/02/08
• Sinovac Announces Phase III Results of Its COVID-19 Vaccine
  2021/02/05
• Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China
  2021/02/03
• Clarification Statement
  2021/01/31
• Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine
  2020/12/09
• Sinovac Reports Unaudited Third Quarter 2020 Financial Results
  2020/12/07
• Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development
  2020/12/07
• Brazil's National Health Surveillance Agency Authorizes Resumption of the Phase III Clinical Trial of CoronaVac™
  2020/11/11
• A Clarification of Interruption in Phase III trial On COVID-19 Vaccine
  2020/11/10
• Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan
  2020/09/28
• Sinovac’s Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children
  2020/09/23
• Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
  2020/09/22
• Sinovac Reports Preliminary Phase I/II Results of COVID-19 Vaccine in Elderly Volunteers
  2020/09/09
• Sinovac Reports Unaudited Second Quarter 2020 Financial Results
  2020/08/28
• Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation
  2020/08/25
• Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial
  2020/07/06
• Sinovac Reports Unaudited First Quarter 2020 Financial Results
  2020/06/30
• Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine
  2020/06/24
• Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19
  2020/06/13
• Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III
  2020/06/11
• Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development
  2020/05/22
• Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital
  2020/05/18
• Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE
  2020/05/06
• Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F
  2020/04/30
• Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19
  2020/04/17
• Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19
  2020/04/14
• Sinovac Amends Shareholder Rights Plan
  2020/02/22
• Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children
  2019/12/27
• Sinovac Reports Unaudited Third Quarter 2019 Financial Results
  2019/11/15
• Sinovac Reports Unaudited Second Quarter 2019 Financial Results
  2019/08/15
• Sinovac Reports Unaudited First Quarter 2019 Financial Results
  2019/07/10
• Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F
  2019/04/29
• Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the JID
  2019/04/16
• Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
  2019/04/13
• Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
  2019/03/08
• Sinovac Determines Trigger Event Occurred Under Rights Agreement
  2019/02/22
• Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital’s Claim; Current Board Was Validly Elected at Annual General Meeting
  2018/12/19
• Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Bei
  2018/12/13
• Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac’s Senior Management
  2018/11/29
• Sinovac Reports Unaudited First Half of 2018 Financial Results
  2018/11/08
• Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
  2018/10/22
• U.S. District Court in Massachusetts Denies 1Globe’s Motion for Preliminary Injunction to Enjoin Sinovac’s Issuance of Shares
  2018/10/17
• Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
  2018/10/16
• Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures
  2018/10/10
• DOJ Closes Investigation of Sinovac
  2018/09/17
• SEC Concludes Investigation of Sinovac
  2018/08/20
• Sinovac Raises $86.73 Million Through Private Placement Transaction
  2018/07/03
• Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court
  2018/06/26
• Sinovac Biotech Relaunches Company Website
  2018/06/11
• Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results
  2018/05/11
• Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
  2018/05/08
• Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
  2018/05/01
• Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
  2018/04/30
• Sinovac Temporarily Blocks Access to Its Websites
  2018/04/30
• Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
  2018/04/27
• Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
  2018/04/27
• Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department
  2018/04/24
• Sinovac Announces Preliminary Results of Phase III Trial on sIPV
  2018/04/19
• Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
  2018/04/18
• Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
  2018/03/27
• Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties
  2018/03/15
• Sinovac Amends Shareholder Rights Plan
  2018/03/07
• Sinovac Announces Enhancement of Corporate Governance and Management of China Operating Entity
  2018/03/06
• Sinovac Announces Re-Election of All Directors at Annual General Meeting
  2018/03/06
• Sinovac Provides Update on Going Private Transaction
  2018/02/07
• Sinovac Holds 2017 Annual General Meeting of Shareholders
  2018/02/07
• Sinovac Schedules 2017 Annual Meeting of Shareholders
  2017/12/29
• Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization
  2017/12/23
• Sinovac Biotech Cures Nasdaq Filing Deficiency
  2017/12/01
• Sinovac Reports Unaudited First Half of 2017 Financial Results
  2017/12/01
• Sinovac Biotech Announces Update on Nasdaq Matters
  2017/11/30
• Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results
  2017/11/23
• Sinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel
  2017/11/09
• Sinovac Biotech Announces Receipt of DelistingDetermination Letter fromNasdaq
  2017/11/04
• Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox
  2017/09/25
• Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual Report on Form 20-F
  2017/08/14
• Sinovac Biotech Ltd. Enters into Definitive Agreement for Going-Private Transaction
  2017/06/26
• Sinovac Biotech Announces Receipt of NASDAQ Letter
  2017/05/17
• Sinovac Reports Announces Filing Extension for 2016 Annual Report
  2017/05/01
• Sinovac Amends Shareholder Rights Plan
  2017/03/24
• Sinovac Responds to Recent Report
  2016/12/23
• Sinovac Reports Unaudited Third Quarter 2016 Financial Results
  2016/11/28
• Sinovac to Host Conference Call to Report Third Quarter 2016 Unaudited Financial Results
  2016/11/15
• Sinovac Announces Results of 2016 Annual General Meeting of Shareholders
  2016/11/07
• Sinovac Product Pipeline News
  2016/10/19
• Sinovac Schedules 2016 Annual Meeting of Shareholders
  2016/09/30
• Sinovac Reports Unaudited Second Quarter 2016 Financial Results
  2016/08/23
• Sinovac to Host Conference Call to Report Second Quarter and 2016 Unaudited Financial Results
  2016/08/15
• Sinovac Reports Unaudited First Quarter 2016 Financial Results
  2016/05/27
• Sinovac to Host Conference Call to Report First Quarter of 2016 Unaudited Financial Results
  2016/05/20
• Sinovac Files 2015 Annual Report on Form 20-F
  2016/04/26
• Sinovac Special Committee Engages Financial and Legal Advisors
  2016/04/14
• Sinovac Reports Unaudited Fourth Quarter and Full Year 2015 Financial Results
  2016/04/05
• Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2015 Unaudited Financial Results
  2016/04/02
• Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights
  2016/03/28
• Sinovac Announces Receipt of Competing Non-Binding “Going Private” Proposal
  2016/02/04
• Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee
  2016/02/01
• Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine
  2016/01/28
• Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine
  2016/01/04
• Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
  2015/12/10
• Sinovac Reports Unaudited Third Quarter Financial Results
  2015/11/12
• Sinovac to Participate in Morgan Stanley Asia Pacific Summit
  2015/11/04
• Sinovac to Host Conference Call to Report Third Quarter 2015 Unaudited Financial Results
  2015/11/02
• Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate
  2015/10/26
• Sinovac Receives Tender to Supply Seasonal Flu Vaccine in Beijing
  2015/09/14
• Sinovac to Participate in Morgan Stanley Global Healthcare Conference
  2015/09/10
• Sinovac Reports Unaudited Second Quarter Financial Results
  2015/08/13
• Sinovac Announces Results of 2015 Annual General Meeting of Shareholders
  2015/08/11
• Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results
  2015/08/04
• Sinovac Schedules 2015 Annual Meeting of Shareholders
  2015/07/08
• Sinovac Reports Unaudited First Quarter 2015 Financial Results
  2015/05/15
• Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities
  2015/05/14
• Sinovac to Participate in UBS Global Healthcare Conference
  2015/05/12
• Sinovac to Host Conference Call to Report First Quarter 2015 Unaudited Financial Results
  2015/05/07
• Sinovac Files 2014 Annual Report on Form 20-F
  2015/04/29
• Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results
  2015/04/20
• Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results
  2015/04/10
• Sinovac to Participate in China Medical and Healthcare Investment Conference
  2015/03/18
• Sinovac Provides Updates on Pipeline Vaccines
  2015/03/17
• Sinovac Reports Unaudited Third Quarter Financial Results
  2014/11/15
• Sinovac Reports Unaudited Third Quarter Financial Results
  2014/11/15
• Sinovac to Host Conference Call to Report Third Quarter 2014 Unaudited Financial Results
  2014/11/05
• Sinovac to Participate in Jefferies 4th Annual Asia Summit
  2014/10/21
• Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference
  2014/09/05
• Sinovac to Participate in Upcoming Investor Conferences
  2014/09/02
• Sinovac Announces Results of 2014 Annual General Meeting of Shareholders
  2014/08/27
• Sinovac Reports Unaudited Second Quarter Financial Results
  2014/08/15
• Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
  2014/07/25
• Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
  2014/07/23
• Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
  2014/07/21
• Sinovac Schedules 2014 Annual Meeting of Shareholders
  2014/07/14
• Sinovac Announces Favorable Reduction in Value Added Tax Rate
  2014/06/25
• Sinovac Reports Unaudited First Quarter 2014 Financial Results
  2014/05/22
• Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results
  2014/05/12
• Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV)
  2014/04/28
• Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project
  2014/04/24
• Sinovac Files 2013 Annual Report on Form 20-F
  2014/04/16
• Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results
  2014/03/20
• Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
  2014/03/12
• Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
  2014/02/27
• Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus
  2014/01/29
• Sinovac Reports Unaudited Third Quarter 2013 Financial Results
  2013/11/13
• Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis Vaccine Healive® under Expanded Immunization Program
  2013/11/07
• Sinovac to Host Conference Call to Report Third Quarter 2013 Unaudited Financial Results
  2013/11/04
• Sinovac to participate in UBS Asia Healthcare CEO Summit in November 2013
  2013/10/31
• Sinovac Holds 2013 Annual General Meeting of Shareholders
  2013/08/21
• Sinovac Reports Unaudited Second Quarter 2013 Financial Results
  2013/08/14
• Sinovac to Host Conference Call to Report Second Quarter 2013 Unaudited Financial Results
  2013/07/31
• Sinovac Schedules 2013 Annual Meeting of Shareholders
  2013/07/19
• Sinovac Appoints New Chief Financial Officer
  2013/06/01
• Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration
  2013/05/30
• Sinovac Reports Unaudited First Quarter 2013 Financial Results
  2013/05/28
• Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
  2013/05/24
• Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results
  2013/05/17
• SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP CHINA AS EXTERNAL AUDITOR
  2013/05/15
• Sinovac Presents at the UBS Global Healthcare Conference in May 2013
  2013/05/14
• Sinovac Files Annual Report on Form 20-F
  2013/04/30
• Sinovac Reports Unaudited Fourth Quarter and Full Year 2012 Financial Results
  2013/04/18
• Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
  2013/04/18
• Sinovac Receives Commercial Approval in Mexico for Seasonal Flu Vaccine
  2013/04/18
• Sinovac Schedules Conference Call and Webcast for Fourth Quarter and Full Year Unaudited Financial Results
  2013/04/02
• Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease
  2013/03/14
• Sinovac Reports Unaudited Third Quarter 2012 Financial Results
  2012/11/15
• Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
  2012/10/29
• Sinovac Awarded Tenders in Beijing and Shanghai to Supply Inactivated Hepatitis A Vaccine Healive^® Under Expanded Immunization Program
  2012/09/25
• Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
  2012/09/18
• Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
  2012/09/10
• Sinovac Holds 2012 Annual General Meeting of Shareholders
  2012/08/23
• Sinovac Reports Unaudited Second Quarter 2012 Financial Results
  2012/08/15
• Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
  2012/08/06
• Sinovac Schedules 2012 Annual Meeting of Shareholders
  2012/07/16
• Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
  2012/06/26
• Sinovac to Present at 5th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
  2012/06/18
• Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial
  2012/06/12
• Sinovac Reports Unaudited First Quarter 2012 Financial Results
  2012/05/15
• Sinovac Names Danny Chung Chief Financial Officer
  2012/05/15
• Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
  2012/05/08
• Sinovac Participates in Goldman Sachs/Gao Hua Healthcare Corporate Day in Hong Kong
  2012/04/12
• Sinovac Files Annual Report on Form 20-F
  2012/04/12
• Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results
  2012/03/29
• Sinovac Announces Director Appointment
  2012/03/29
• Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine
  2012/03/29
• Sinovac to Host Conference Call to Report Fourth Quarter 2011 Unaudited Financial Results
  2012/03/22
• Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement
  2012/01/24
• Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
  2012/01/10
• Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
  2012/01/04
• Sinovac Reports Unaudited Third Quarter 2011 Financial Results
  2011/11/14
• Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
  2011/11/09
• Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
  2011/11/08
• Sinovac Selected by Beijing CDC to Supply Seasonal Influenza Vaccine Anflu(R) to Beijing Citizens
  2011/10/17
• Sinovac's Animal Rabies Vaccine RabEnd Receives Production License
  2011/09/27
• Sinovac Reports Unaudited Second Quarter 2011 Financial Results
  2011/08/12
• Sinovac Receives GMP Certificate in Mexico for Seasonal Flu Vaccine and Hepatitis A Vaccine
  2011/08/11
• Sinovac Announces Management Changes
  2011/08/05
• Sinovac to Host Conference Call to Report Second Quarter 2011 Unaudited Financial Results
  2011/08/01
• Sinovac Holds 2011 Annual Shareholders Meeting
  2011/07/15
• Sinovac Commences Phase II Clinical Trial for EV71 Vaccine
  2011/06/28
• Sinovac to Present at 5th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
  2011/06/19
• Sinovac Schedules 2011 Annual Meeting of Shareholders
  2011/06/08
• Sinovac Appoints Kenneth Lee to Board of Directors
  2011/05/31
• Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
  2011/05/25
• Sinovac Reports Unaudited First Quarter 2011 Financial Results
  2011/05/13
• Sinovac Presents at Two Investor Conferences in May 2011
  2011/05/10
• Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
  2011/05/04
• Sinovac Files Annual Report on Form 20-F
  2011/04/23
• Sinovac Reports Fourth Quarter and Full Year 2010 Financial Results
  2011/03/31
• Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
  2011/03/28
• Sinovac Participates in UBS Greater China Healthcare Corporate Day
  2011/03/25
• Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
  2011/03/10
• Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
  2011/03/03
• Sinovac Presents at Rodman & Renshaw Annual China Investment Conference
  2011/03/01
• Sinovac Biotech Files Clinical Trial Applications with SFDA for its Proprietary Pneumococcal Polysaccharides Vaccines (PPV)
  2011/01/31
• Sinovac Participates in UBS Greater China Conference 2011
  2011/01/31
• Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
  2011/01/06
• Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine
  2010/12/28
• Sinovac Reports Unaudited Third Quarter 2010 Financial Results
  2010/11/15
• Sinovac to Host Conference Call to Report Third Quarter 2010 Unaudited Financial Results
  2010/11/01
• Sinovac Participates in Two Investor Conferences in November
  2010/10/27
• Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
  2010/10/25
• Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
  2010/10/25
• Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
  2010/10/25
• Sinovac Reports Unaudited Second Quarter 2010 Financial Results
  2010/08/16
• Sinovac to Host Conference Call to Report Second Quarter 2010 Financial Results
  2010/08/10
• Sinovac Holds 2010 Annual Meeting of Shareholders
  2010/07/15
• Sinovac Schedules 2010 Annual Meeting of Shareholders
  2010/06/18
• Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
  2010/06/01
• Sinovac to Participate at 2010 Shanghai CPhI Exhibition
  2010/05/28
• Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
  2010/05/24
• Sinovac Reports Unaudited First Quarter 2010 Financial Results
  2010/05/14
• Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
  2010/05/07
• Sinovac Submits Clinical Trial Application for Mumps Vaccine to SFDA
  2010/05/06
• Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results
  2010/04/06
• Sinovac to Host Conference Call to Report 2009 Fourth Quarter Financial Results
  2010/03/30
• Sinovac Enters Exclusive Supply and Distribution Agreements with Parenteral Biotech Ltd. for India
  2010/03/30
• Sinovac to Present at Inaugural China Healthcare Investment Conference
  2010/03/24
• Sinovac Completes Acquisition Aimed at Expanding Production Capacity
  2010/02/24
• Sinovac Announces Closing of Common Share Offering
  2010/02/03
• Sinovac Announces Exercise of Over-Allotment Option
  2010/02/02
• Sinovac Announces Upsizing and Pricing of Common Share Offering
  2010/01/28
• Sinovac Announces Plan to Launch Offering of Common Shares
  2010/01/21
• Sinovac Announces Recent Developments
  2010/01/21
• /C O R R E C T I O N -- Sinovac Biotech Ltd.
  2010/01/14
• Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
  2010/01/13
• Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
  2009/12/28
• Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
  2009/12/28
• Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009
  2009/12/22
• Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award
  2009/12/15
• Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
  2009/12/02
• Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
  2009/11/25
• Sinovac to Present at Piper Jaffray Health Care Conference
  2009/11/25
• Sinovac Files Shelf Registration Statement
  2009/11/18
• Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
  2009/11/18
• Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive®
  2009/11/16
• Sinovac Reports Unaudited Third Quarter 2009 Financial Results
  2009/11/16
• Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results
  2009/11/11
• Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market
  2009/11/03
• Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
  2009/10/28
• Sinovac Receives Certificate of Approval to Distribute PANFLU.1 (H1N1) in Mexico
  2009/10/22
• Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
  2009/09/30
• Sinovac to Present at 2009 UBS Global Life Sciences Conference
  2009/09/16
• Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
  2009/09/08
• Hong Kong Department of Health Visited Sinovac on R&D and Production of H1N1 vaccine
  2009/09/08
• Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
  2009/09/04
• Sinovac Obtains Production License for H1N1 Vaccine
  2009/09/03
• Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
  2009/09/02
• Sinovac’s H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
  2009/09/01
• Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
  2009/08/31
• Sinovac Reports Top-Line Preliminary Results of H1N1 Vaccine Clinical Trials
  2009/08/19
• Sinovac Reports Unaudited Second Quarter 2009 Financial Results
  2009/08/19
• Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
  2009/08/12
• Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
  2009/08/04
• Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
  2009/07/23
• IP Biotech and Sinovac Enter Partnership Agreement
  2009/07/09
• Sinovac Schedules 2008 Annual General Meeting
  2009/07/01
• Sinovac Receives Revised Approvals for Panflu
  2009/07/01
• Sinovac Receives China's First Influenza A (H1N1) Vaccine Order
  2009/06/19
• Sinovac Begins the Production of Influenza A (H1N1) Vaccine
  2009/06/10
• China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
  2009/06/03
• Sinovac Reports Unaudited First Quarter 2009 Financial Results
  2009/05/15
• Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
  2009/05/11
• Sinovac Biotech Ltd. Files Annual Report on Form 20-F
  2009/05/02
• Sinovac Receives RMB 87 Million Purchase Order for Healive from China
  2009/05/01
• Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
  2009/04/30
• Beijing Mayor Visited Sinovac on Promoting Development of Biopharmaceutical Industry
  2009/04/27
• CORRECTION-- Sinovac Biotech Ltd.
  2009/04/10
• Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
  2009/04/09
• Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
  2009/04/02
• Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status
  2009/03/10
• Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
  2009/03/03
• Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
  2009/01/26
• Sinovac Announces that Government Investigation Rules Out Healive
  2009/01/03
• Sinovac Named to Zhongguancun's Top 20 Most Influential Brands
  2008/12/22
• Sinovac Announces Share Repurchase Program
  2008/12/03
• Sinovac Releases Statement on Healive Vaccine Suspension
  2008/12/03
• Sinovac to Host Conference Call to Report Third Quarter 2008 Financial Results
  2008/11/13
• Sinovac Named to Deloitte Technology Fast 50 China
  2008/11/04
• Sinovac to Participate in Two Upcoming Investor Conferences
  2008/10/30
• Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating
  2008/10/10
• Sinovac to Present at the 2008 UBS Global Life Sciences Conference
  2008/09/26
• Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
  2008/09/25
• Sinovac Initiates Development of Vaccine Against Hand, Foot, and Mouth Disease
  2008/09/23
• Sinovac Biotech Increases Ownership Position in its Operating Subsidiary Sinovac Beijing
  2008/09/22
• Sinovac Biotech Holds 2007 Annual General Meeting
  2008/09/19
• Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
  2008/09/16
• Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
  2008/09/11
• Sinovac Adjourns Annual General Meeting
  2008/09/04
• Sinovac to Present at the Susquehanna Financial Group's Second Annual Beijing Management Summit Conference
  2008/09/02
• Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
  2008/08/15
• Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
  2008/08/12
• Sinovac to Host Conference Call to Report Second Quarter 2008 Financial Results
  2008/08/10
• Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
  2008/06/30
• Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
  2008/06/17
• Sinovac Delivers 80,000 Doses of Bilive to Gansu Earthquake Disaster Area
  2008/06/12
• Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims
  2008/05/28
• Sinovac Provides Support to China's Ministry of Health to Aid Earthquake Victims
  2008/05/22
• Sinovac Reports First Quarter 2008 Unaudited Financial Results
  2008/05/16
• Sinovac to Host Conference Call to Report First Quarter 2008 Financial Results
  2008/05/16
• Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
  2008/05/08
• Sinovac Biotech Holds Annual General Meeting
  2008/04/10
• Sinovac Receives SFDA's Approval for Pandemic Influenza H5N1 Vaccine
  2008/04/02
• Sinovac Published Annual Report 2007 (20-F)
  2008/04/01
• Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
  2008/03/31
• Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
  2008/03/26
• Sinovac Announces Adjournment of Annual General Meeting
  2008/03/25
• Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
  2008/03/25
• Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
  2008/02/20
• Sinovac Closes $9.75 Million Private Placement
  2008/02/04
• Sinovac Announces $9.75 Million Private Placement
  2008/01/24
• Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
  2007/12/26
• Sinovac Requests Extension for Annual Shareholders Meeting
  2007/12/14
• Sinovac's Hepatitis A Vaccine Healive Selected by Beijing Centers For Diseases Control and Prevention
  2007/12/14
• Sinovac Reports Third Quarter 2007 Unaudited Financial Results
  2007/12/12
• Sinovac Files Form 6-K with SEC
  2007/11/21
• Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
  2007/11/21
• Sinovac Enters Purchase Agreement with Beijing Public Health Bureau for Anflu, Sinovac's Seasonal Influenza Vaccine
  2007/11/05
• Sinovac to Present at 2007 UBS Global Life Sciences Conference
  2007/09/21
• Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
  2007/09/21
• Sinovac Announces Postponement of Annual General Meeting
  2007/09/21
• Sinovac Reports First Half 2007 Financial Results
  2007/08/16
• Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1)
  2007/08/15
• Sinovac Schedules First Half 2007 Financial Results Date
  2007/08/14
• Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd.
  2007/08/02
• Sinovac Schedules Annual General Meeting
  2007/08/01
• Sinovac Receives Full Payment for Heping Wang's Obligations
  2007/07/30
• Sinovac Issues Corporate Update
  2007/07/30
• Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1)
  2007/05/10
• Sinovac to Present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
  2007/05/10
• Sinovac Reports 2006 Financial Results
  2007/05/10
• Sinovac Reports First Quarter 2007 Unaudited Sales
  2007/05/10
• Sinovac Schedules 2006 Financial Results Date
  2007/04/10
• Sinovac Provides Update on Study of Third Dose of Its Pandemic Influenza Vaccine
  2007/03/12
• FIRST HUMAN CASE IN 2007 REPORTED
  2007/03/02
• Sinovac Files Registration Documents for Euvax-B(TM) with SFDA Loan Repayment Received from One Former Director
  2007/02/09
• Sinovac Schedules Investor Conference Call for February 6, 2007
  2007/02/05
• Sinovac Clarifies Position on Restructuring Involving Its Chinese Subsidiary
  2007/02/02
• Sinovac Reports Fourth Quarter 2006 Unaudited Sales and Provides Corporate Update for 2007
  2007/01/17
• Sinovac Issues Corporate Update
  2006/11/29
• Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations And Public Relations Counsel
  2006/10/17
• Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM)
  2006/09/28
• Sinovac Reports Semi-Annual Results
  2006/09/13
• Sinovac Announces Its Clinical Trial Results of a Pandemic Influenza (H5N1) Vaccine Are Published by The Lancet
  2006/09/08
• Preliminary Result of Phase I Clinical Trial Shows That Sinovac's Pandemic Influenza Vaccine (H5N1) has High Safety and Immunogenicity Profile
  2006/08/29
• Sinovac Biotech Ltd. Changes Its Contact for Investor Relations
  2006/08/03
• Ludlow Capital Adds Sinovac to China Small Cap Index
  2006/07/20
• Sinovac Reports Fiscal 2005 Results
  2006/07/15
• Sinovac Biotech Files Form 12b-25 with the U.S. Securities and Exchange Commission
  2006/07/03
• Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of its Proprietary Avian Influenza Vaccine (H5N1)
  2006/04/11
• Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce Distribution Agreement to Market Vaccines in the Peoples Republic of China
  2006/03/14
• Sinovac Biotech Ltd. to Hold Annual Meeting of Stockholders and Business Objectives for 2006
  2006/02/28
• Sinovac Receives Approval to Commence Human Clinical Trials for Pandemic Influenza Vaccine
  2005/11/23
• Sinovac Passes China’s Ministry of Science and Technology “Pandemic Influenza Vaccine R&D Project” Examination
  2005/11/15
• Sinovac Receives GMP Certification for its Seasonal Influenza Vaccine, AnFlu
  2005/10/27
• Sinovac to present at the UBS Global Life Sciences Conference and Announces Additional Funding
  2005/09/21
• Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
  2005/09/12
• WHO Meeting Held to Review the Results of Sinovac SARS Vaccine Phase I Trial and Discuss Phase II Protocols
  2005/09/12
• China’s new Vaccine Distribution System, and its Impact on Sinovac Biotech Ltd.
  2005/09/12
• Sinovac Biotech Ltd. Announces First Sales of its Proprietary Combined Hepatitis A&B Vaccine, BiliveTM
  2005/09/12
• Sinovac Biotech Ltd. Retains Segue Ventures, LLC for Investor Relations and Public Relations
  2005/09/12
• SINOVAC BIOTECH LTD. REPORTS 2004 SALES GROWTH OF 127 %
  2005/09/12
• Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce their Letter of Intent for Collaboration in Global Marketing and Vaccine Supply
  2005/09/12
• SINOVAC BIOTECH LTD. ANNOUNCES THAT IT HAS LAUNCHED THE MARKETING OF ITSPROPRIETARY COMBINED HEPATITIS A&B VACCINE, BILIVE™
  2005/09/12
• SINOVAC BIOTECH LTD. ANOUNCES THAT IT HAS RECEIVED THE NEW DRUG CERTIFICATE FROM THE CHINESE GOVERNMENT FOR ITS SPLIT FLU VACCINE
  2005/09/12
• Sinovac Biotech Ltd.: Updates on its Avian Influenza Vaccine Development
  2005/09/12
• Sinovac Biotech Ltd. Announces Final Approval by the Chinese FDA (SFDA) for Bilive"TM", its Proprietary Combined Hepatitis A&B Vaccine
  2005/09/12
• SINOVAC BIOTECH LTD. LISTED ON HALTER USX CHINA INDEX
  2005/09/12